Cardinal Health Inc (New York Stock Exchange:CAH)
| Market Cap | $63.69B+32.5% |
| Revenue (ttm) | $257.75B+10.0% |
| Net Income | $1.82B+14.0% |
| EPS | $7.72+16.4% |
| Shares Out | 231.14M |
| PE Ratio | 35.55 |
| Forward PE | 19.12 |
| Dividend | $2.05(0.75%) |
| Ex-Dividend Date | Jan 4, 2027 |
| Volume | 413,194 |
| Open | $276.52 |
| Previous Close | $272.34 |
| Day's Range | $273.46 - $276.52 |
| 52-Week Range | $180.45 - $286.29 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | $288.27(+4.62%) |
| Earnings Date | Feb 4, 2027 |
About CAH
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating CAH in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Jan 4, 2027Ex-dividend date
- Feb 4, 2027Earnings report
$CAH stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CAH by members of U.S. Congress
| Alan ArmstrongSenate / R | Purchase$1.00K – $15.00K | Mar 27, 2026 |
| Jonathan JacksonHouse / D | Purchase$50.00K – $100.00K | Jan 12, 2024 |
| Jonathan JacksonHouse / D | Purchase$50.00K – $100.00K | Jan 11, 2024 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 18, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 18, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 17, 2020 |
Recently reported changes in CAH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CAH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CAH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CAH Revenue by Segment or Geography
| Pharmaceutical and Specialty Solutions | $62.58B | 92.66% |
| GMPD | $3.19B | 4.72% |
| Other Operating Segment | $1.76B | 2.61% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CAH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CAH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CAH
| VOOVanguard S&P 500 ETF | $1.55B |
| VTIVanguard Morningstar Total Stock Market ETF | $1.46B |
| VOVanguard Morningstar Mid-Cap ETF | $1.24B |
| IVViShares Core S&P 500 ETF | $853.32M |
| SPYState Street SPDR S&P 500 ETF | $788.49M |
| VTVVanguard Morningstar Value ETF | $560.05M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CAH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrades on price targets offset medical device recalls; mixed but slightly bullish on fundamentals.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| EGGS | NestYield Total Return Guard ETF | 6.86% |
| PEZ | Invesco Dorsey Wright Consumer Cyclicals Momentum ETF | 5.84% |
| EASY | Liberty One Defensive Dividend Growth ETF | 5.44% |
| HLTH | Tema Healthcare AI ETF | 4.84% |
| FXG | First Trust Consumer Staples AlphaDEX Fund | 4.76% |
| BTAL | AGF U.S. Market Neutral Anti-Beta Fund | 4.73% |
| HIG.TO | Brompton Global Healthcare Income & Growth ETF | 4.60% |
| HIG-U.TO | Brompton Global Healthcare Income & Growth ETF | 4.60% |
| GBLO | Global Beta Low Beta ETF | 4.57% |
| BASV | Brown Advisory Sustainable Value ETF | 4.21% |
| GBDV | Global Beta Smart Income ETF | 4.17% |
| BLCR | iShares Large Cap Core Active ETF | 4.09% |
Weight is the stock’s share of each fund’s holdings.
